These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 20553282)

  • 21. Long stents as a risk factor for late stent thrombosis size does matter.
    Tommaso CL
    JACC Cardiovasc Interv; 2010 Apr; 3(4):390-1. PubMed ID: 20398865
    [No Abstract]   [Full Text] [Related]  

  • 22. Optimizing the impact of primary percutaneous coronary intervention in acute myocardial infarction.
    Satler LF
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):201. PubMed ID: 21290554
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment options for patients with left main coronary artery disease.
    Lee MS; Nguyen J
    Rev Cardiovasc Med; 2011; 12(2):e77-83. PubMed ID: 21796086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stent thrombosis with drug-eluting stents: a re-examination of the evidence.
    Kedia G; Lee MS
    Catheter Cardiovasc Interv; 2007 May; 69(6):782-9. PubMed ID: 17394249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate "rosy" prophecy.
    Wykrzykowska JJ; Onuma Y; Serruys PW
    EuroIntervention; 2009 Dec; 5 Suppl F():F7-8. PubMed ID: 22100680
    [No Abstract]   [Full Text] [Related]  

  • 26. It's not the dye, but the "die" in dialysis: which coronary revascularization strategy really is best?
    Butman SM
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):949-50. PubMed ID: 21108371
    [No Abstract]   [Full Text] [Related]  

  • 27. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravascular ultrasound-guided percutaneous coronary interventions in contemporary practice.
    Bonello L; De Labriolle A; Lemesle G; Roy P; Steinberg DH; Pichard AD; Waksman R
    Arch Cardiovasc Dis; 2009 Feb; 102(2):143-51. PubMed ID: 19303582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients.
    Miglionico M; Patti G; D'Ambrosio A; Di Sciascio G
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):600-4. PubMed ID: 18360849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of diabetics receiving bare-metal stents versus drug-eluting stents.
    Ramanath VS; Brown JR; Malenka DJ; DeVries JT; Sidhu MS; Robb JF; Jayne JE; Hettleman BD; Friedman BJ; Niles NW; Kaplan AV; Thompson CA;
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):473-81. PubMed ID: 20882647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
    Ducrocq G; Serebruany V; Tanguay JF
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis.
    Lemesle G; Sudre A; Modine T; Delhaye C; Rosey G; Gourlay T; Bauters C; Lablanche JM
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):470-8. PubMed ID: 18814219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
    Lasala JM; Cox DA; Dobies D; Baran K; Bachinsky WB; Rogers EW; Breall JA; Lewis DH; Song A; Starzyk RM; Mascioli SR; Dawkins KD; Baim DS;
    Circ Cardiovasc Interv; 2009 Aug; 2(4):285-93. PubMed ID: 20031730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Percutaneous coronary intervention and stent thrombosis].
    Sugaya T; Igarashi K
    Nihon Rinsho; 2011 Feb; 69(2):275-9. PubMed ID: 21387676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral sirolimus after bare metal stent implantation: a glimpse to the future.
    Mieres J
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):158-9. PubMed ID: 20931667
    [No Abstract]   [Full Text] [Related]  

  • 37. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
    Sarafoff N; Sibbing D; Sonntag U; Ellert J; Schulz S; Byrne RA; Mehilli J; Schömig A; Kastrati A
    Thromb Haemost; 2010 Sep; 104(3):626-32. PubMed ID: 20664905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Left main and high-risk PCI: what, exactly, is it high risk for?
    Safian RD
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):952-3. PubMed ID: 21598347
    [No Abstract]   [Full Text] [Related]  

  • 40. Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent.
    Xu B; Zhang Q; Yang YJ; Qiao SB; Zhang RY; Zhang JS; Hu J; Qin XW; Hong T; Li JP; Chen JL; Huo Y; Gao RL; Shen WF
    Chin Med J (Engl); 2008 Mar; 121(6):492-7. PubMed ID: 18364131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.